质子泵抑制剂的使用增加了炎症性肠病发作的次数

B. Yildirim, Yusuf Bünyamin Ketenci, U. Avcıoğlu, İ. Gören, T. Ayyildiz, Muge Ustaoglu, A. Bektaş
{"title":"质子泵抑制剂的使用增加了炎症性肠病发作的次数","authors":"B. Yildirim, Yusuf Bünyamin Ketenci, U. Avcıoğlu, İ. Gören, T. Ayyildiz, Muge Ustaoglu, A. Bektaş","doi":"10.5152/diagnintervendosc.2022.222132","DOIUrl":null,"url":null,"abstract":"Objective: Proton pump inhibitors may alter intestinal microbiota, and changes in intestinal microbiota may lead to the activation of inflammatory bowel disease. In our study, we investigated the association between proton pump inhibitor use and inflammatory bowel disease activation. Methods: A total of 67 inflammatory bowel disease patients were enrolled in this study. The number of inflammatory bowel disease episodes, medications used, and the use of proton pump inhibitors were evaluated retrospectively for all patients. We divided the patients into 2 groups as proton pump inhibitor users and non-proton pump inhibitor users, and the groups were compared. Results: The median age of the 67 inflammatory bowel disease patients (41 male and 26 female) was 37 (18-70) years. The disease duration since diagnosis was 63.4 (10.2-223.6) months, and the total number of episodes was 3.0 (0-20). Crohn’s disease was diagnosed in 23 patients (34.3%) and ulcerative colitis in 44 (65.7%) patients. Of the patients, 35 (52.2%) were on anti-tumor necrosis factor treatment and 41 (61.2%) had proton pump inhibitor usage history for a median of 40 (1-300) months. Among 41 proton pump inhibitor users, 34 (82.9%) had a history of inflammatory bowel disease activation during the course of treatment. When proton pump inhibitor users and non-proton pump inhibitor users were compared in terms of disease duration, there was no difference ( P = .65); however, the number of inflammatory bowel disease episodes was significantly different (5.0 (0-20) episodes vs. 1.5 (0-17) episodes, respectively; P < .0001). Conclusion: In patients with inflammatory bowel disease, proton pump inhibitor use may be associated with an increase in the incidence of disease episodes. Randomized, controlled studies involving more patients will guide to clarify the uncertain points of this finding.","PeriodicalId":427772,"journal":{"name":"Diagnostic and Interventional Endoscopy","volume":"5 4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of Proton Pump Inhibitors Increases the Number of Episodes of Inflammatory Bowel Disease\",\"authors\":\"B. Yildirim, Yusuf Bünyamin Ketenci, U. Avcıoğlu, İ. Gören, T. Ayyildiz, Muge Ustaoglu, A. Bektaş\",\"doi\":\"10.5152/diagnintervendosc.2022.222132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Proton pump inhibitors may alter intestinal microbiota, and changes in intestinal microbiota may lead to the activation of inflammatory bowel disease. In our study, we investigated the association between proton pump inhibitor use and inflammatory bowel disease activation. Methods: A total of 67 inflammatory bowel disease patients were enrolled in this study. The number of inflammatory bowel disease episodes, medications used, and the use of proton pump inhibitors were evaluated retrospectively for all patients. We divided the patients into 2 groups as proton pump inhibitor users and non-proton pump inhibitor users, and the groups were compared. Results: The median age of the 67 inflammatory bowel disease patients (41 male and 26 female) was 37 (18-70) years. The disease duration since diagnosis was 63.4 (10.2-223.6) months, and the total number of episodes was 3.0 (0-20). Crohn’s disease was diagnosed in 23 patients (34.3%) and ulcerative colitis in 44 (65.7%) patients. Of the patients, 35 (52.2%) were on anti-tumor necrosis factor treatment and 41 (61.2%) had proton pump inhibitor usage history for a median of 40 (1-300) months. Among 41 proton pump inhibitor users, 34 (82.9%) had a history of inflammatory bowel disease activation during the course of treatment. When proton pump inhibitor users and non-proton pump inhibitor users were compared in terms of disease duration, there was no difference ( P = .65); however, the number of inflammatory bowel disease episodes was significantly different (5.0 (0-20) episodes vs. 1.5 (0-17) episodes, respectively; P < .0001). Conclusion: In patients with inflammatory bowel disease, proton pump inhibitor use may be associated with an increase in the incidence of disease episodes. Randomized, controlled studies involving more patients will guide to clarify the uncertain points of this finding.\",\"PeriodicalId\":427772,\"journal\":{\"name\":\"Diagnostic and Interventional Endoscopy\",\"volume\":\"5 4 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diagnostic and Interventional Endoscopy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5152/diagnintervendosc.2022.222132\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic and Interventional Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/diagnintervendosc.2022.222132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:质子泵抑制剂可能改变肠道菌群,肠道菌群的改变可能导致炎症性肠病的激活。在我们的研究中,我们调查了质子泵抑制剂的使用与炎症性肠病激活之间的关系。方法:共纳入67例炎症性肠病患者。对所有患者的炎症性肠病发作次数、使用的药物和质子泵抑制剂的使用进行回顾性评估。我们将患者分为质子泵抑制剂使用者和非质子泵抑制剂使用者两组,并对两组进行比较。结果:67例炎症性肠病患者(男性41例,女性26例)的中位年龄为37岁(18-70岁)。自诊断以来病程63.4(10.2 ~ 223.6)个月,总发作次数3.0次(0 ~ 20次)。克罗恩病23例(34.3%),溃疡性结肠炎44例(65.7%)。其中,35例(52.2%)患者接受抗肿瘤坏死因子治疗,41例(61.2%)患者有质子泵抑制剂使用史,中位时间为40(1-300)个月。在41名质子泵抑制剂使用者中,34名(82.9%)在治疗过程中有炎症性肠病活化史。当质子泵抑制剂使用者和非质子泵抑制剂使用者在疾病持续时间方面进行比较时,没有差异(P = 0.65);然而,炎症性肠病发作次数显著不同(5.0(0-20)次vs. 1.5(0-17)次;P < 0.0001)。结论:在炎症性肠病患者中,质子泵抑制剂的使用可能与疾病发作的发生率增加有关。涉及更多患者的随机对照研究将有助于澄清这一发现的不确定性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Use of Proton Pump Inhibitors Increases the Number of Episodes of Inflammatory Bowel Disease
Objective: Proton pump inhibitors may alter intestinal microbiota, and changes in intestinal microbiota may lead to the activation of inflammatory bowel disease. In our study, we investigated the association between proton pump inhibitor use and inflammatory bowel disease activation. Methods: A total of 67 inflammatory bowel disease patients were enrolled in this study. The number of inflammatory bowel disease episodes, medications used, and the use of proton pump inhibitors were evaluated retrospectively for all patients. We divided the patients into 2 groups as proton pump inhibitor users and non-proton pump inhibitor users, and the groups were compared. Results: The median age of the 67 inflammatory bowel disease patients (41 male and 26 female) was 37 (18-70) years. The disease duration since diagnosis was 63.4 (10.2-223.6) months, and the total number of episodes was 3.0 (0-20). Crohn’s disease was diagnosed in 23 patients (34.3%) and ulcerative colitis in 44 (65.7%) patients. Of the patients, 35 (52.2%) were on anti-tumor necrosis factor treatment and 41 (61.2%) had proton pump inhibitor usage history for a median of 40 (1-300) months. Among 41 proton pump inhibitor users, 34 (82.9%) had a history of inflammatory bowel disease activation during the course of treatment. When proton pump inhibitor users and non-proton pump inhibitor users were compared in terms of disease duration, there was no difference ( P = .65); however, the number of inflammatory bowel disease episodes was significantly different (5.0 (0-20) episodes vs. 1.5 (0-17) episodes, respectively; P < .0001). Conclusion: In patients with inflammatory bowel disease, proton pump inhibitor use may be associated with an increase in the incidence of disease episodes. Randomized, controlled studies involving more patients will guide to clarify the uncertain points of this finding.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信